RT Journal Article
SR Electronic
T1 Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12–17 year-old adolescents
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.22.23286317
DO 10.1101/2023.02.22.23286317
A1 Lopez, Pio
A1 Bravo, Lulu
A1 Buntinx, Erik
A1 Borja-Tabora, Charissa
A1 Velasquez, Hector
A1 Rodriguez, Edith Johana
A1 Rodriquez, Camilo A.
A1 Carlos, Josefina
A1 Montellano, May Emmeline B.
A1 Alberto, Edison R.
A1 Salvani-Bautista, Milagros
A1 Huang, Yung
A1 Hu, Branda
A1 Li, Ping
A1 Han, Htay Htay
A1 Baccarini, Carmen
A1 Smolenov, Igor
YR 2023
UL http://medrxiv.org/content/early/2023/02/26/2023.02.22.23286317.abstract
AB We previously demonstrated efficacy of the COVID-19 vaccine candidate, SCB-2019, in adults in the SPECTRA phase 2/3 efficacy study. We extended the study to include 1278 healthy 12–17-year-old adolescents in Belgium, Colombia and the Philippines who received either two doses of SCB-2019 or placebo 21 days apart, to assess immunogenicity as neutralizing antibodies against prototype SARS-CoV-2 and variants of concern, and safety and reactogenicity as solicited and unsolicited adverse events with a comparator group of young adults (18–25 years). In participants with no evidence of prior SARS-CoV-2 infection SCB-2019 immunogenicity in adolescents was non-inferior to that in young adults; respective geometric mean neutralizing titers (GMT) against prototype SARS-CoV-2 14 days after the second vaccination were 271 IU/mL (95% CI: 211–348) and 144 IU/mL (116–178). Most adolescents (1077, 84.3%) had serologic evidence of prior SAR-CoV-2 exposure at baseline; in these seropositive adolescents neutralizing GMTs increased from 173 IU/mL (135–122) to 982 IU/mL (881–1094) after the second dose. Neutralizing titers against Delta and Omicron BA SARS-CoV-2 variants were also increased, most notably in those with prior exposure.SCB-2019 vaccine was well tolerated with generally mild or moderate, transient solicited and unsolicited adverse events that were comparable in adolescent vaccine and placebo groups except for injection site pain – reported after 20% of SCB-2019 and 7.3% of placebo injections. SCB-2019 vaccine was highly immunogenic against SARS-CoV-2 prototype and variants in adolescents, especially in those with evidence of prior exposure, with comparable immunogenicity to young adults.Clinical trial registration EudraCT 2020-004272-17; ClinicalTrials.gov NCT04672395.Competing Interest StatementYH, BH, PL, HHH, CB and IS are full-time employees of Clover Biopharmaceuticals. Other authors have no interest to declare.Clinical TrialNCT04405908Funding StatementThis work was supported by grants from Coalition for Epidemic Preparedness Innovations (CEPI), grant number PRJ-6052.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of European Medicines Agency gave ethical approval for this work Ethics committee of China Center for Drug Evaluation gave ethical approval for this work Ethics committee of Anvisa Brazil gave ethical approval for this work Ethics committee of the Philippines Food and Drug Administration gave ethical approval for this work I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets, including the redacted study protocol, redacted statistical analysis plan, and individual participants data supporting the results reported in this article, will be available three months from initial request, to researchers who provide a methodologically sound proposal. The data will be provided after its de-identification, in compliance with applicable privacy laws, data protection and requirements for consent and anonymization.